Intellectual Property


Q-Sera’s technology is based upon research emanating from the University of Queensland and is patent protected.

Family 1 Priority Date Sept 2010

'Serum Preparation'
PCTAU2011/001221

This patent covers all prothrombin activators from snake venom including naturally occurring and recombinant versions in blood collection tubes for the production of serum for biochemical analysis.

July 2018: Patent granted or approved in EU, Japan, China, Mexico, Russia and Australia.
Patent pending in US, South Korea, India, Israel, Canada, Brazil and South Africa.

Family 2 Priority Date Oct 2014

'Improved Clotting Composition'
PCTAU2015/000629

Covers formulations to enhance the temperature and irradiation stability of snake venom prothrombin activators in blood collection tubes.

Examination ongoing.